## Pengfei Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8356321/publications.pdf Version: 2024-02-01



DENCEEL WANC

#	Article	IF	CITATIONS
1	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature, 2021, 593, 130-135.	27.8	1,904
2	Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature, 2020, 584, 450-456.	27.8	1,337
3	A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell, 2020, 27, 125-136.e7.	11.1	543
4	Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host and Microbe, 2021, 29, 747-751.e4.	11.0	504
5	Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host and Microbe, 2021, 29, 819-833.e7.	11.0	444
6	Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature, 2021, 589, 270-275.	27.8	389
7	Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains. Cell Host and Microbe, 2020, 28, 867-879.e5.	11.0	316
8	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature, 2021, 595, 278-282.	27.8	154
9	Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Research, 2013, 41, 7771-7782.	14.5	146
10	Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host and Microbe, 2022, 30, 1077-1083.e4.	11.0	132
11	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	27.8	117
12	SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerging Microbes and Infections, 2020, 9, 2091-2093.	6.5	109
13	Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerging Microbes and Infections, 2022, 11, 477-481.	6.5	104
14	Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York. Nature, 2021, 597, 703-708.	27.8	103
15	Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter. Molecular Therapy, 2016, 24, 508-521.	8.2	67
16	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports, 2020, 33, 108322.	6.4	59
17	The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Scientific Reports, 2016, 6, 24100.	3.3	56
18	Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Cell Reports, 2021, 35, 108950.	6.4	54

Pengfei Wang

#	Article	IF	CITATIONS
19	Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure, 2021, 29, 655-663.e4.	3.3	52
20	Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. Cell Reports, 2021, 37, 109928.	6.4	52
21	Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. Virology, 2013, 440, 182-189.	2.4	51
22	Integrative analyses of transcriptomics and metabolomics upon seed germination of foxtail millet in response to salinity. Scientific Reports, 2020, 10, 13660.	3.3	45
23	Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 lgG1 antibodies in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18002-18009.	7.1	44
24	Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. Scientific Reports, 2017, 7, 9451.	3.3	40
25	An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. Circulation Research, 2021, 129, 33-46.	4.5	40
26	Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. Cell Reports, 2021, 37, 109771.	6.4	38
27	Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secretingÂCCL2. Stem Cell Reports, 2021, 16, 2274-2288.	4.8	37
28	An airway organoid-based screen identifies a role for the HIF1α-glycolysis axis in SARS-CoV-2 infection. Cell Reports, 2021, 37, 109920.	6.4	36
29	Selective Histonedeacetylase Inhibitor M344 Intervenes in HIV-1 Latency through Increasing Histone Acetylation and Activation of NF-kappaB. PLoS ONE, 2012, 7, e48832.	2.5	35
30	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. Clinical Microbiology Reviews, 2022, 35, .	13.6	35
31	Two cellular microRNAs, miR-196b and miR-1290, contribute to HIV-1 latency. Virology, 2015, 486, 228-238.	2.4	34
32	CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. Scientific Reports, 2020, 10, 5350.	3.3	30
33	As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB. Antiviral Research, 2013, 100, 688-697.	4.1	25
34	A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes and Infections, 2022, 11, 147-157.	6.5	25
35	Cytokine cascade and networks among MSM HIV seroconverters: implications for early immunotherapy. Scientific Reports, 2016, 6, 36234.	3.3	23
36	Direct observation of the work function evolution of graphene-two-dimensional metal contacts. Journal of Materials Chemistry C, 2014, 2, 8042-8046.	5.5	21

Pengfei Wang

#	Article	IF	CITATIONS
37	Designed Transcription Activator-Like Effector Proteins Efficiently Induced the Expression of Latent HIV-1 in Latently Infected Cells. AIDS Research and Human Retroviruses, 2015, 31, 98-106.	1.1	15
38	Direct Deposition of Uniform High- $\hat{I}^{\circ}$ Dielectrics on Graphene. Scientific Reports, 2014, 4, 6448.	3.3	14
39	Zinc finger nuclease: a new approach for excising HIV-1 proviral DNA from infected human T cells. Molecular Biology Reports, 2014, 41, 5819-5827.	2.3	13
40	Angiotensin converting enzyme 2 is a novel target of the Î <sup>3</sup> -secretase complex. Scientific Reports, 2021, 11, 9803.	3.3	13
41	Reactivation of latent HIV-1 in latently infected cells by coumarin compounds: Hymecromone and ScoparoneReactivation of Latent HIV-1 in Latently Infected Cells by Coumarin Compounds: Hymecromone and Scoparone. Current HIV Research, 2016, 14, 484-490.	0.5	9
42	The Investigation of Field Plate Design in 500 V High Voltage NLDMOS. Advances in Condensed Matter Physics, 2015, 2015, 1-6.	1.1	6
43	Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains. SSRN Electronic Journal, 0, , .	0.4	6
44	Dilazep synergistically reactivates latent HIV-1 in latently infected cells. Molecular Biology Reports, 2014, 41, 7697-7704.	2.3	5
45	Antibody screening at reduced <scp>pH</scp> enables preferential selection of potently neutralizing antibodies targeting <scp>SARSâ€CoV</scp> â€2. AICHE Journal, 2021, 67, e17440.	3.6	4
46	Design of high reliability RF-LDMOS by suppressing the parasitic bipolar effect using enhanced p-well and double epitaxy. Journal of Semiconductors, 2015, 36, 064013.	3.7	3
47	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. SSRN Electronic Journal, 2020, , 3639618.	0.4	3
48	Oxaliplatin antagonizes HIV-1 latency by activating NF-κB without causing global T cell activation. Biochemical and Biophysical Research Communications, 2014, 450, 202-207.	2.1	2
49	Anti-HIV Passive Immunization in Animal Models. Journal of HIV & Retro Virus, 2018, 04, .	0.0	2
50	Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses. SSRN Electronic Journal, 0, , .	0.4	1
51	Genome-wide characterization of Rice Black Streaked Dwarf Virus-responsive genes in rice. SDRP Journal of Food Science & Technology, 2020, 5, 66-82.	0.2	1